Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,964 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02995655 | CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia | completed | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Dec 5, 2019 | clinicaltrials |
| NCT02391480 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | completed | Phase 1 | 128 | AbbVieINDUSTRY | 1 | Nov 29, 2019 | clinicaltrials |
| NCT01446081 | An Exercise Trial for Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy | completed | Phase 2 | 83 | University Health Network, TorontoOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT00321581 | AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2019 | clinicaltrials |
| NCT01012492 | Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT | completed | Phase 2 | 11 | Boston Children's HospitalOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT01707004 | Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 20 | University of Wisconsin, MadisonOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00652626 | Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function(RENAL) | completed | Phase 1 | 31 | CelgeneINDUSTRY | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02909972 | Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | completed | Phase 1 | 55 | Aileron Therapeutics, Inc.INDUSTRY | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02164071 | Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies(GAH) | completed | — | 363 | CelgeneINDUSTRY | 1 | Nov 18, 2019 | clinicaltrials |
| NCT01929408 | Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients | completed | — | 703 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT01829503 | Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 2 | 44 | Annie Im, M.D.OTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT00856388 | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders | completed | N/A | 62 | Roswell Park Cancer InstituteOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT00761722 | Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma(RACE) | completed | Phase 1 | 31 | CelgeneINDUSTRY | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00105001 | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 210 | Fred Hutchinson Cancer CenterOTHER | 3 | Oct 30, 2019 | clinicaltrials |
| NCT02129101 | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | completed | Phase 1 | 63 | Mayo ClinicOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT02527447 | Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in People With Relapsed or Refractory Acute Myeloid Leukemia (PEARL15) | completed | — | 15 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Oct 30, 2019 | clinicaltrials |
| NCT01702155 | Phase I/II Study of DFP-10917 in Patients With Acute Leukemia | completed | Phase 1 / Phase 2 | 69 | Delta-Fly Pharma, Inc.INDUSTRY | 1 | Oct 25, 2019 | clinicaltrials |
| NCT00101179 | MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | completed | Phase 1 | 63 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2019 | clinicaltrials |
| NCT03442452 | AML Electronic Decision Aid | completed | N/A | 20 | Duke UniversityOTHER | 1 | Oct 15, 2019 | clinicaltrials |
| NCT01743859 | Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia | completed | Phase 2 | 37 | University of Colorado, DenverOTHER | 1 | Oct 8, 2019 | clinicaltrials |
| NCT03526666 | Ascorbic Acid Levels in MDS, AML, and CMML Patients | completed | — | 50 | Van Andel Research InstituteOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01529827 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 94 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01305200 | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant | completed | Phase 3 | 226 | Children's Oncology GroupNETWORK | 3 | Sep 17, 2019 | clinicaltrials |
| NCT00260832 | Trial of Decitabine in Patients With Acute Myeloid Leukemia | completed | Phase 3 | 485 | Eisai Inc.INDUSTRY | 15 | Sep 11, 2019 | clinicaltrials |
| NCT00005799 | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | N/A | 55 | Fred Hutchinson Cancer CenterOTHER | 2 | Sep 10, 2019 | clinicaltrials |
| NCT00620321 | A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 24 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 9, 2019 | clinicaltrials |
| NCT02666950 | WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 3 | Mayo ClinicOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT02674763 | Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia | completed | Phase 1 | 62 | ImmunoGen, Inc.INDUSTRY | 1 | Sep 4, 2019 | clinicaltrials |
| NCT02474290 | Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML | completed | Phase 2 / Phase 3 | 202 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT01519596 | Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy | completed | N/A | 70 | Wake Forest University Health SciencesOTHER | 1 | Aug 16, 2019 | clinicaltrials |
| NCT01839916 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 77 | University of ChicagoOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01537159 | MRI Assessment of Leukemia Response to Therapy | completed | — | 23 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT00374933 | Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation | completed | Phase 1 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT00780104 | Sirolimus in Combination With MEC in High Risk Myeloid Leukemias(UPCC 02407) | completed | Phase 1 | 16 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT00510133 | A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 21 | Asterias Biotherapeutics, Inc.INDUSTRY | 1 | Jul 9, 2019 | clinicaltrials |
| NCT02920541 | Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome | completed | Phase 1 | 48 | Institut de Recherches Internationales ServierOTHER | 2 | May 24, 2019 | clinicaltrials |
| NCT00895934 | Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2019 | clinicaltrials |
| NCT00414310 | Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 153 | M.D. Anderson Cancer CenterOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT02856204 | Shotgun Sequencing in Diagnosing Febrile Neutropenia in Patients With Acute Myeloid Leukemia | completed | — | 56 | Stanford UniversityOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT02602587 | Study of Dendrogenin A / Oxysterols Balance Between Healthy Volunteers and Acute Myeloid Leukemia Patients(OXYLAM) | completed | N/A | 37 | University Hospital, ToulouseOTHER | 1 | May 13, 2019 | clinicaltrials |
| NCT00413166 | All-trans Retinoic Acid, and Arsenic +/- Idarubicin | completed | Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT01463046 | Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | completed | Phase 1 | 29 | University of California, San FranciscoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT01700751 | Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation | completed | Phase 1 | 17 | Washington University School of MedicineOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01295710 | Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) | completed | Phase 3 | 260 | Neovii BiotechINDUSTRY | 2 | Apr 9, 2019 | clinicaltrials |
| NCT02492737 | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | completed | Phase 1 | 46 | Agios Pharmaceuticals, Inc.INDUSTRY | 2 | Mar 8, 2019 | clinicaltrials |
| NCT01175785 | Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies | completed | Phase 2 | 15 | Nohla Therapeutics, Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01031368 | Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 29 | Nohla Therapeutics, Inc.INDUSTRY | 1 | Mar 1, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Dec 5, 2019source: clinicaltrials